Tech Company Financing Transactions
Solid Biosciences Funding Round
On 3/31/2017, Solid Biosciences raised $50 million in Series C funding from Bain Capital Ventures, RA Capital and Biogen Idec.
Transaction Overview
Company Name
Announced On
3/31/2017
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Bain Capital Ventures (Lead Investor) (Adam Koppel)
RA Capital (Lead Investor) (Rajeev Shah)
Proceeds Purpose
The proceeds will enable us to move SGT-001 through clinical development and maintain momentum in our efforts to identify and develop a new generation of meaningful DMD therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
141 Portland St. 5th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Solid Biosciences is a Cambridge, MA-based life science company committed to solving Duchenne muscular dystrophy and improving the lives of patients. Solid is currently developing gene therapies, disease modifying therapies and assistive devices, all targeting the many facets of the disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Andrey Zarur
Chief Executive Officer
Ilan Ganot
Chief Medical Officer
Jorge Quiroz
Chief Operating Officer
Alvaro Amorrortu
Chief Scientific Officer
Carl Morris
Chief Technical Officer
Joel Schneider
VP - Finance
Lynne Sullivan
Browse more venture capital transactions:
Prev: 3/31/2017: Voxy venture capital transaction
Next: 3/31/2017: Prioria Robotics venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on tech company VC transactions. VC transactions reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs